19.09.2018 | Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers
MUNICH, Germany and COLOGNE, Germany, September 19, 2018-- Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.
The partnership provides customers with high-performance instrument platforms from Nanion and Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. Under the current one-year program, Nanion and Ncardia join forces to offer a menu of packages that address a spectrum of throughput requirements and budgets. The packages include state-of-the-art cell monitoring instrumentation: Nanion’s CardioExcyte 96 instrument with a SOL optical stimulation add-on option, and a supply of Ncardia´s iPSC-derived cardiomyocytes – either frozen or delivered via ‘ready-to-use’ CardioPlates™. Cor.4U® cardiomyocytes, validated in the CiPA consortium, are ideally suited for impedance applications, addressing structural as well as functional cardiotoxicity.
Niels Fertig, CEO Nanion Techologies, says:
“In Ncardia, Nanion sees a strong business partner, but also a partner in development and science as demonstrated through our joint pioneering efforts in developing optogenetic stimulation solutions. This, and many other successful joint projects, brought us together in this program, as well.”
Read the full press release here.